433.07
-20.67 (-4.56%)
| Penutupan Terdahulu | 453.74 |
| Buka | 450.95 |
| Jumlah Dagangan | 1,915,411 |
| Purata Dagangan (3B) | 1,440,454 |
| Modal Pasaran | 110,014,586,880 |
| Harga / Pendapatan (P/E TTM) | 28.25 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.81 |
| Harga / Jualan (P/S) | 9.76 |
| Harga / Buku (P/B) | 6.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 May 2026 |
| Margin Keuntungan | -8.91% |
| Margin Operasi (TTM) | 37.22% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.00% |
| Nisbah Semasa (MRQ) | 2.65 |
| Aliran Tunai Operasi (OCF TTM) | -980.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.63 B |
| Pulangan Atas Aset (ROA TTM) | 11.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vertex Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 97.64% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 641.00 (HC Wainwright & Co., 48.01%) | Beli |
| Median | 558.00 (28.85%) | |
| Rendah | 441.00 (Canaccord Genuity, 1.83%) | Pegang |
| Purata | 557.40 (28.71%) | |
| Jumlah | 12 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 488.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 11 Mar 2026 | 525.00 (21.23%) | Beli | 492.38 |
| B of A Securities | 10 Mar 2026 | 598.00 (38.08%) | Beli | 499.17 |
| Citigroup | 10 Mar 2026 | 585.00 (35.08%) | Beli | 499.17 |
| HC Wainwright & Co. | 10 Mar 2026 | 641.00 (48.01%) | Beli | 499.17 |
| 17 Feb 2026 | 591.00 (36.47%) | Beli | 477.32 | |
| Jefferies | 10 Mar 2026 | 580.00 (33.93%) | Beli | 499.17 |
| Morgan Stanley | 10 Mar 2026 | 596.00 (37.62%) | Beli | 499.17 |
| Oppenheimer | 10 Mar 2026 | 600.00 (38.55%) | Beli | 499.17 |
| 13 Feb 2026 | 540.00 (24.69%) | Beli | 491.47 | |
| Barclays | 17 Feb 2026 | 607.00 (40.16%) | Beli | 477.32 |
| 28 Jan 2026 | 606.00 (39.93%) | Beli | 477.91 | |
| Canaccord Genuity | 17 Feb 2026 | 441.00 (1.83%) | Pegang | 477.32 |
| RBC Capital | 13 Feb 2026 | 541.00 (24.92%) | Beli | 491.47 |
| 22 Jan 2026 | 546.00 (26.08%) | Beli | 467.35 | |
| Scotiabank | 13 Feb 2026 | 558.00 (28.85%) | Pegang | 491.47 |
| Stifel | 13 Feb 2026 | 466.00 (7.60%) | Pegang | 491.47 |
| UBS | 26 Jan 2026 | 545.00 (25.85%) | Beli | 476.84 |
| 07 Jan 2026 | 535.00 (23.54%) | Beli | 484.15 | |
| Evercore ISI Group | 23 Jan 2026 | 530.00 (22.38%) | Beli | 468.41 |
| Wolfe Research | 06 Jan 2026 | 548.00 (26.54%) | Beli | 468.38 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager |
| 29 Jan 2026 | Pengumuman | Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs |
| 26 Jan 2026 | Pengumuman | Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets |
| 20 Jan 2026 | Pengumuman | Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th |
| 11 Jan 2026 | Pengumuman | Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings |
| 02 Jan 2026 | Pengumuman | Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |